EMV Capital commercial update spotlights XF-73 ahead of Phase 3
EMV Capital (AIM:EMVC) issued a commercial update highlighting the progress of XF-73, the nasal decolonisation candidate in its portfolio, as it advances toward a Phase 3 programme. The update emphasised that the leadership team at the relevant portfolio company, AMR Bio, backed by figures including Nigel Brooksby, Dr Ilian Iliev, and Dr William Rhys-Williams, is executing across regulatory strategy, manufacturing, commercial planning and stakeholder engagement simultaneously. The shares rose 3.23% to 48.0p on the update.
XF-73 targets antibiotic-resistant bacterial colonisation ahead of surgical procedures, a space attracting growing regulatory and commercial interest. The update framed the current phase as one of coordinated preparation rather than a single binary event, with multiple workstreams running in parallel as the asset approaches the Phase 3 threshold.
IXICO wins £1.3 million Alzheimer's and Huntington's clinical analytics contracts
IXICO (AIM:IXI) announced two new contract awards with a combined value of £1.3 million over two years, covering analytics for an Alzheimer's blood-based biomarker study and imaging analysis in a Phase 2 Huntington's Disease trial. The wins add to IXICO's established position as a specialist provider of neuroimaging and data analytics services to the clinical trial market. New commercial director Bram Goorden joined the business ahead of the announcement. The shares slipped 2.35% to 8.3p despite the news.
Oxford Nanopore names first Chief Medical Officer and new CIO
Oxford Nanopore Technologies (LSE:ONT) made two senior appointments, hiring Davide Manissero as its first-ever Chief Medical Officer and Andrew Watson as Chief Information Officer, alongside existing leadership from Tina St Leger, Francis Van Parys, and Nick Keher. The creation of a CMO role is a structural step for the sequencing company as it pushes further into clinical and diagnostic applications for its nanopore platform. The shares gained 1.23% to 123.2p.
Deutsche Bank repeats Sell on AstraZeneca despite "frenetic" pipeline news
AstraZeneca (LSE:AZN) attracted a pointed broker note from Deutsche Bank, which acknowledged the company's pipeline activity as "frenetic" but maintained its Sell rating and 11,500p price target, implying roughly 18% downside from current levels. Analyst Emmanuel Papadakis was cited in the note. The stock edged up 0.34% to 13,998p, leaving the gap between the market price and Deutsche Bank's target at its widest in recent weeks.
